Estimation of the projections of the incidence rates, mortality and prevalence due to common cancer site in Isfahan, Iran

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3581-3585

  Moradpour, Farhad ^a   Fatemi, Zeinab ^a  

^a KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Estimate; Incidence; Iran; Isfahan; Mortality; Prevalence

Indexed keywords

EID: 84882597626     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3581     Document Type: Article

References (38)

1. Adami H-O, Hunter DJ, Trichopoulos D (2008). Textbook of cancer epidemiology. New York ; Oxford, Oxford University Press.
2. Ali Mohagheghi M, Mosavi-Jarrahi A (2010). Review of cancer registration and cancer data in Iran, a historical prospect. Asian Pac J Cancer Prev, 11, 1155-7.
3. Ashktorab H, Daremipouran M, Wilson M, et al (2007). Transactivation of the EGFR by AP-1 is induced by Helicobacter pylori in gastric cancer. Am J Gastroenterol, 102, 2135-46.
4. Babaei M, Jaafarzadeh H, Sadjadi A, et al (2009). Cancer incidence and mortality in ardabil: report of an an j publ health on going population-based cancer registry in Iran, 2004-2006. Iranian J Publ Health, 38, 35-45.
5. Bidgoli SA, Eftekhari T, Sadeghipour R (2011). Role of xenoestrogens and endogenous sources of estrogens on the occurrence of premenopausal breast cancer in Iran. Asian Pac J Cancer Prev, 12, 2425-30.
6. Center for Disease Control and Prevention, Noncommunicable Deputy Cancer Office. Iranian Annual National Cancer Registration Report 2003-2009 [in Persian]. Tehran (Iran): Ministry of Health and Medical Education; 2010.
7. De Angelis G, De Angelis R, Frova L, Verdecchia A (1994). MIAMOD: a computer package to estimate chronic disease morbidity using mortality and survival data. Comput Methods Programs Biomed, 44, 99-107.
8. Derakhshan MH, Malekzadeh R, Watabe H, et al (2008). Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut, 57, 298-305.
9. Etemadi A, Sadjadi A, Semnani S, et al (2008). Cancer registry in Iran: a brief overview. Arch Iran Med, 11, 577-80.
10. Ferlay J, International Agency for Research on Cancer. (2001). GLOBOCAN (2000) cancer incidence, mortality, and prevalence worldwide. [IARC Cancer Base no 5]. Lyon, IARCPress: 1 CD-ROM.
11. Francisci S, Capocaccia R, Grande E, et al (2009). The cure of cancer: a European perspective. Eur J Cancer, 45, 1067-79.
12. Ghiasvand R, Maram ES, Tahmasebi S, Tabatabaee SH (2011). Risk factors for breast cancer among young women in southern Iran. Int J Cancer, 129, 1443-9.
13. Grande E, Inghelmann R, Francisci S, et al (2007). Regional estimates of all cancer malignancies in Italy. Tumori, 93, 345-51.
14. Grande E, Inghelmann R, Francisci S, et al (2007). Regional estimates of breast cancer burden in Italy. Tumori, 93, 374-9.
15. Grande E, Inghelmann R, Francisci S, et al (2006). Estimating regional cancer burden in countries with partial registration coverage: an application to all malignant neoplasms in Italy over the period 1970-2010. Eur J Cancer, 42, 3236-45.
16. Inghelmann R, Grande E, Francisci S, et al (2007). Regional estimates of lung cancer burden in Italy. Tumori, 93, 360-6.
17. James RE, Lukanova A, Dossus L, et al (2011). Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res, 4, 1626-35.
18. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
19. Maracy MR, Moradpour F, Hosseini SM, Tirani M (2012). Cancer incidence and prevalence in isfahan: application of mortality data to estimates and projects for the period 2001- 2015. Int J Prev Med, 3, 867-74.
20. Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M (2009). Cancer incidence in Tehran metropolis: the first report from the Tehran population-based cancer registry, 1998-2001. Arch Iran Med, 12, 15-23.
21. Mokarian F, Ramezani MA, Heydari K, Tabatabaeian M, Tavazohi H (2011). Epidemiology and trend of cancer in Isfahan 2005-2010. J Res Med Sci, 16, 1228-33.
22. Moller H, Fairley L, Coupland V, et al (2007). The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer, 96, 1484-8.
23. Montazeri A, Sadighi J, Farzadi F, et al (2008). Weight, height, body mass index and risk of breast cancer in postmenopausal women: a case-control study. BMC Cancer, 8, 278.
24. Mousavi SM (2009). Toward prostate cancer early detection in Iran. Asian Pac J Cancer Prev, 10, 413-8.
25. Mousavi SM, Alamolhoda AA, Gouya MM, Lickiss N (2008). Implementation of comprehensive national cancer control program in Iran: an experience in a developing country. Ann Oncol, 19, 398-400.
26. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
27. National Cancer Registration Report 2004-2005 [in Persian]. Tehran (Iran): Ministry of Health and Medical Education; 2005.
28. Parkin DM (2006). The evolution of the population-based cancer registry. Nat Rev Cancer, 6, 603-12.
29. Ravakhah K (2006). Death certificates are not reliable: Revivification of the autopsy. Southern Med J, 99, 728-33.
30. Sadjadi A, Nooraie M, Ghorbani A, et al (2007). The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med, 10, 481-5.
31. Sadjadi A, Zahedi M, Moghadam SD, et al (2007). The first population-based cancer survey in Kerman Province of Iran. Iranian J Publ Health, 36, 26-34.
32. Sanchez MJ, Payer T, De Angelis R, et al (2010). Cancer incidence and mortality in Spain: estimates and projections for the period 1981-2012. Ann Oncol, 21, 30-6.
33. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
34. Swaminathan R, Brenner H (2011). Stastistical methods for cancer survival analysis. IARC Sci Publ, 162, 7-13.
35. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM (2010). The global burden of cancer: priorities for prevention. Carcinogenesis, 31, 100-10.
36. Verdecchia A, Capocaccia R, Egidi V, Golini A (1989). A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med, 8, 201-16.
37. Verdecchia A, De Angelis R, Francisci S, Grande E (2007). Methodology for estimation of cancer incidence, survival and prevalence in Italian regions. Tumori, 93, 337-44.
38. Verdecchia A, Mariotto A, Capocaccia R, et al (2001). Incidence and prevalence of all cancerous diseases in Italy: trends and implications. Eur J Cancer, 37, 1149-57.